CancerNCT07831148
Music Therapy Program for Patients in Palliative Care (MUSPAL360)
A study testing Music Therapy with Virtual Reality (Session 1), Significant Song Choice (Session 2) and Biographical Musical Legacy (Session 3) in people with Cancer and Palliative Care, run by Austral University, Argentina.
Trial summary
Hospitalized patients with advanced cancer often experience a heavy burden of physical, emotional, and spiritual symptoms that affect their quality of life. This study will evaluate whether a structured, three-session music therapy program called MUSPAL360 can be feasibly delivered to hospitalized adult patients with… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cancer, Palliative Care
- What is being tested?
- Music Therapy with Virtual Reality (Session 1), Significant Song Choice (Session 2) and Biographical Musical Legacy (Session 3)
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- No sites listed yet
- Study dates
- 1 Oct 2026to 1 Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult patients ≥18 years of age with advanced cancer, defined using the NECPAL-CCOMS instrument Hospitalized in the Internal Medicine Service or the Integral Care Unit (UCIA) of HUA and attended by the Palliative Care team Expected hospital stay of at least 7 consecutive days at the time of inclusion (per treating medical team's judgment) Willing to participate and able to sign Informed Consent after receiving a full explanation from the Principal Investigator At least one symptom scoring ≥7 points on the ESAS-r scale Able to maintain alertness and adequate responsiveness during 30-45 minute sessions Able to maintain a bed position of at least 45° for use of the virtual reality headset No cognitive impairment, defined as 0-2 errors on the Short Portable Mental Status Questionnaire (SPMSQ-Pfeiffer), with correction for educational level per the original instrument Functional hearing sufficient to listen to music (with or without hearing aids)
Who cannot join
- Patients in active agonal phase (last 48-72 hours of life, per medical team's judgment) Active, uncontrolled delirium, assessed using the Confusion Assessment Method (CAM) Epilepsy or history of photosensitive seizures Requiring palliative sedation for refractory symptoms Strict contact isolation precluding entry of musical instruments and equipment into the room
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Feasibility Study of the MUSPAL360 Music Therapy Program in Adult Patients With Advanced Oncological Disease in Palliative Care at HUA
Hospitalized patients with advanced cancer often experience a heavy burden of physical, emotional, and spiritual symptoms that affect their quality of life. This study will evaluate whether a structured, three-session music therapy program called MUSPAL360 can be feasibly delivered to hospitalized adult patients with advanced cancer receiving palliative care at Hospital Universitario Austral (HUA).
MUSPAL360 includes three sessions delivered over about one week during hospitalization:
Read more
Music therapy combined with virtual reality, focused on support and relaxation. Selection of personally meaningful songs, focused on communication and expression.
Creation of a musical life story based on chronological biographical questions, focused on transformation.
Family caregivers may participate in the sessions if the patient agrees. All participants receive standard palliative care in addition to the music therapy program; there is no control group and no randomization.
This is a feasibility study, not a study designed to test whether the program works. The main goals are to determine the proportion of eligible patients, the proportion who consent to participate, how many complete each session, how complete the collected data are, and whether any adverse events occur. The study also collects preliminary, exploratory information on symptom burden and spiritual wellbeing before and after the program, to help plan the sample size of a future confirmatory study.
The researchers plan to enroll a minimum of 40 hospitalized patients, anticipating substantial attrition between sessions due to the clinical course of advanced illness in this population.
Read the detailed description
Patients with advanced oncological disease experience a high symptom burden - including pain, fatigue, dyspnea, anxiety, and depression - that significantly impacts quality of life, functioning, and overall wellbeing. These symptoms frequently co-occur and intensify in the final months of life, creating multidimensional suffering that requires comprehensive approaches beyond conventional pharmacological management. However, evidence on structured non-pharmacological interventions in palliative care units remains scarce, representing less than 5% of published randomized controlled trials in this field.
Music therapy has shown positive effects in hospitalized oncology patients, including reductions in anxiety, depression, fatigue, and pain. A prior single-session study combining music therapy with virtual reality conducted by this research group demonstrated statistically significant reductions in prevalent symptoms compared to a no-intervention control group. However, a gap remains in the literature regarding the effectiveness of multiple-session interventions and their cumulative effects over time. A systematic review conducted by the research group identified only six controlled studies evaluating multiple-session music therapy interventions in patients with advanced cancer, revealing methodological limitations including a lack of standardized protocols, heterogeneity in intervention techniques, and small sample sizes.
To address these limitations, the MUSPAL360 program was designed following recent standardized frameworks for music-based intervention reporting, and validated through a multidisciplinary expert panel (31 experts) using the Content Validity Index, with S-CVI/Ave between 0.916 and 1.000 across all professional groups.
This study adopts a prospective, single-arm, pre-post design. All eligible patients who consent to participate receive the MUSPAL360 program in addition to standard palliative care, with no control group or randomization. A qualitative component is embedded within the study, collecting participants' and caregivers' subjective experience at the end of each session through a funnel-style question guide; qualitative data are analyzed independently and subsequently integrated with quantitative results.
As a feasibility study, MUSPAL360 does not test confirmatory hypotheses. Instead, pre-specified progression criteria (covering eligibility, consent, session-by-session attrition, data completeness, and adverse events) will inform the decision on whether to proceed to a future confirmatory study. The stepwise decline in expected attrition thresholds across sessions reflects the anticipated clinical deterioration typical of hospitalized palliative care populations, rather than a study design limitation.
Sample size was determined by the precision required to estimate feasibility metrics, not by statistical power to detect clinical effects. A minimum of 40 participants will be recruited, accounting for expected attrition at each stage of the program (approximately 20% prior to Session 1, 30% between Sessions 1 and 2, and 40-50% between Sessions 2 and 3), resulting in an estimated 13-15 evaluable participants at program completion. This sample size allows feasibility proportions to be estimated with 95% confidence intervals of approximately ±15-16 percentage points, adequate precision to guide the viability of future studies. Statistical analysis will be predominantly descriptive: progression criteria will be reported as proportions with 95% confidence intervals (Clopper-Pearson exact method), and exploratory secondary outcomes will be analyzed without correction for multiple comparisons or confirmatory interpretation.
- Conditions
- Cancer, Palliative Care
- Being tested
- Music Therapy with Virtual Reality (Session 1), Significant Song Choice (Session 2), Biographical Musical Legacy (Session 3)
- Keywords
- music therapy, pallaitive care, Feasibility Study, Virtual Reality, Symptom Burden, Spiritual Wellbeing, Advanced Cancer, Life Review, Song Choice
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Music Therapy with Virtual Reality (Session 1)Behavioural
First session of the MUSPAL360 program (30/40 minutes), combining live music therapy with immersive 360° virtual reality experiences (Oculus Quest 2) focused on relaxation and support. The music therapist adjusts musical parameters in real time based on the patient's vital signs. Family members may participate through guided imagery with the same live music.
Significant Song Choice (Session 2)Behavioural
Second session of the MUSPAL360 program (45 minutes), using a structured guided-question format for the patient to select biographically meaningful songs, live-performed or played, followed by verbal processing of emotional experiences. Family may participate in the collaborative song selection.
Biographical Musical Legacy (Session 3)Behavioural
Third session of the MUSPAL360 program (45 minutes), using five chronological biographical questions to guide a musical life review. The session is audio-recorded to create a legacy playlist delivered to the patient and/or family via link or QR code.
| Study group | Role | What they receive |
|---|---|---|
| MUSPAL360 | Experimental | All eligible patients who consent to participate receive the three-session MUSPAL360 music therapy program (music therapy with virtual reality, significant song choice, and biographical musical legacy) in addition to standard palliative care. There is no control group or randomization Receives: Behavioral: Music Therapy with Virtual Reality (Session 1); Behavioral: Significant Song Choice (Session 2); Behavioral: Biographical Musical Legacy (Session 3) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Eligibility Rate
Proportion of patients identified by the CP team who meet inclusion criteria (progression threshold: ≥50%)
Measured: Through study completion, an average of 15 months
Consent Rate
Proportion of eligible patients who consent to participate (≥70%)
Measured: Through study completion, an average of 15 months
Session 1 Arrival Rate
Proportion of participants who initiate Session 1 (≥70%)
Measured: Up to 7 days after enrollment
Session 1 Completion Rate
Proportion of initiated Session 1s completed without interruption (≥80%)
Measured: Up to 7 days after enrollment
Session 2 Arrival Rate
Proportion of participants who initiate Session 2 (≥60%)
Measured: Up to 7 days after enrollment
Session 2 Completion Rate
Proportion of initiated Session 2s completed without interruption (≥80%)
Measured: Up to 7 days after enrollment
Session 3 Arrival Rate
Proportion of participants who initiate Session 3 (≥50%)
Measured: Through study completion
Session 3 Completion Rate
Proportion of initiated Session 3s completed without interruption (≥80%)
Measured: Through study completion, an average of 15 months
Data Completeness
Proportion of required REDCap fields completed, calculated over sessions actually performed (≥80%)
Measured: Up to 7 days after enrollment
Adverse Event Rate
Proportion of sessions with adverse events attributable to the intervention (dizziness/nausea from VR headset, significant emotional distress, session interruption due to intolerance, or need for immediate clinical intervention) (<5%)
Measured: Up to 7 days after enrollment
Secondary outcomes (8)
Change in Global Symptom Burden (ESAS-r)
Edmonton Symptom Assessment System-revised (ESAS-r). Sum of 9 symptom items, each scored 0 (no symptom) to 10 (worst possible severity). Total score range: 0-90. Higher scores indicate greater symptom burden (worse outcome).
Measured: Immediately before and after each of the 3 sessions, and at program completion, up to 7 days after enrollment
Change in Spiritual Wellbeing (FACIT-Sp-12, Argentine validation)
Visual Analogue Scale (VAS), single item, range 0-10. Higher scores indicate greater perceived relaxation (better outcome).
Measured: Immediately before and after Session 1 only, up to 7 days after enrollment
Change in Perceived Relaxation (VAS)
Visual Analogue Scale (VAS), single item, range 0-10. Higher scores indicate greater perceived social support (better outcome).
Measured: Immediately before and after Session 2 only, up to 7 days after enrollment
Change in Perceived Social Support (VAS)
Visual Analogue Scale (VAS), single item, range 0-10. Higher scores indicate greater perceived social support (better outcome).
Measured: Immediately before and after Session 2 only, up to 7 days after enrollment
Patient Global Rating of the Program
Ad hoc single-item Likert scale, range 1-5. Higher scores indicate a more positive rating of the program (better outcome).
Measured: Time Frame: At program completion, up to 7 days after enrollment
Caregiver Global Rating of the Program
Ad hoc single-item Likert scale, range 1-5. Higher scores indicate a more positive rating of the program (better outcome).
Measured: At program completion, up to 7 days after enrollment
Patient Subjective Experience (Qualitative)
Explored via an opening question and optional funnel-style follow-up questions. Qualitative data, not a scale score.
Measured: After each of the 3 sessions and at program completion, up to 7 days after enrollment
Caregiver Subjective Experience (Qualitative)
Explored via an opening question and optional funnel-style follow-up questions. Qualitative data, not a scale score.
Measured: After each of the 3 sessions and at program completion, up to 7 days after enrollment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Sep 2026
- Study start1 Oct 2026 (estimated)
- Primary completion1 Oct 2027 (estimated)
- Study completion1 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- This is a single-arm feasibility study. All eligible participants who consent receive the three-session MUSPAL360 music therapy program in addition to standard palliative care. There is no control group or randomization; the study was designed as single-arm following ethics committee guidance regarding randomization in this vulnerable, hospitalized population
- Masking
- None (open label)
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Austral University, Argentina
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Maria Julia Cremona, Austral University, Argentina
- Investigators
- Agustina Iturri, Principal investigator, Austral University, Argentina
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07831148
- Sponsor's protocol ID
- MUSPAL360-2026
- Other IDs
- P26-043
- Status last verified
- Sep 2026
- First submitted
- 10 Sep 2026
- Last updated
- 21 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Dneaster D, Dileo C. Levels of practice in music therapy at the end of life. In: Dileo C, Loewy J, editors. Music Therapy at the End of Life. Cherry Hill: Jeffrey Books; 2005.
Iturri A, Najun M, Vazquez N, Alonso-Babarro A. Music therapy interventions on symptom management in adults with advanced cancer - multisession longitudinal impact: systematic review. BMJ Support Palliat Care. 2026 Aug 28;16(5):1034-1042. doi: 10.1136/spcare-2025-005913.
PubMed 41922094Iturri A, Bertella A, Dovidas MN, Spector J, Alonso Babarro A. Music Therapy Combined with Virtual Reality Reduces Prevalent Symptoms in Adult Patients with Advanced Cancer: Randomized Clinical Trial. J Palliat Med. 2026 May;29(5):594-601. doi: 10.1177/10966218251407902. Epub 2026 Jan 9.
PubMed 42219716
Study at a glance
From the registry record, last updated by the sponsor on 21 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Feasibility Study of the MUSPAL360 Music Therapy Program in Adult Patients With Advanced Oncological Disease in Palliative Care at HUA
- ClinicalTrials.gov ID
- NCT07831148
- Acronym / sponsor ID
- MUSPAL360-2026
- Conditions
- Cancer, Palliative Care
- Keywords
- music therapy, pallaitive care, Feasibility Study, Virtual Reality, Symptom Burden, Spiritual Wellbeing, Advanced Cancer, Life Review
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Austral University, ArgentinaUniversity, hospital or other
- Study start
- 1 Oct 2026 (estimated)
- Primary completion
- 1 Oct 2027 (estimated)
- Study completion
- 1 Dec 2027 (estimated)
- First posted
- 21 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Hospitalized patients with advanced cancer often experience a heavy burden of physical, emotional, and spiritual symptoms that affect their quality of life. This study will evaluate whether a structured, three-session music therapy program called MUSPAL360 can be feasibly delivered to hospitalized adult patients with advanced cancer receiving palliative care at Hospital Universitario Austral (HUA).
MUSPAL360 includes three sessions delivered over about one week during hospitalization:
Music therapy combined with virtual reality, focused on support and relaxation. Selection of personally meaningful songs, focused on communication and expression.
Creation of a musical life story based on chronological biographical questions, focused on transformation.
Family caregivers may participate in the sessions if the patient agrees. All participants receive standard palliative care in addition to the music therapy program; there is no control group and no randomization.
This is a feasibility study, not a study designed to test whether the program works. The main goals are to determine the proportion of eligible patients, the proportion who consent to participate, how many complete each session, how complete the collected data are, and whether any adverse events occur. The study also collects preliminary, exploratory information on symptom burden and spiritual wellbeing before and after the program, to help plan the sample size of a future confirmatory study.
The researchers plan to enroll a minimum of 40 hospitalized patients, anticipating substantial attrition between sessions due to the clinical course of advanced illness in this population.
Detailed description
Patients with advanced oncological disease experience a high symptom burden - including pain, fatigue, dyspnea, anxiety, and depression - that significantly impacts quality of life, functioning, and overall wellbeing. These symptoms frequently co-occur and intensify in the final months of life, creating multidimensional suffering that requires comprehensive approaches beyond conventional pharmacological management. However, evidence on structured non-pharmacological interventions in palliative care units remains scarce, representing less than 5% of published randomized controlled trials in this field.
Music therapy has shown positive effects in hospitalized oncology patients, including reductions in anxiety, depression, fatigue, and pain. A prior single-session study combining music therapy with virtual reality conducted by this research group demonstrated statistically significant reductions in prevalent symptoms compared to a no-intervention control group. However, a gap remains in the literature regarding the effectiveness of multiple-session interventions and their cumulative effects over time. A systematic review conducted by the research group identified only six controlled studies evaluating multiple-session music therapy interventions in patients with advanced cancer, revealing methodological limitations including a lack of standardized protocols, heterogeneity in intervention techniques, and small sample sizes.
To address these limitations, the MUSPAL360 program was designed following recent standardized frameworks for music-based intervention reporting, and validated through a multidisciplinary expert panel (31 experts) using the Content Validity Index, with S-CVI/Ave between 0.916 and 1.000 across all professional groups.
This study adopts a prospective, single-arm, pre-post design. All eligible patients who consent to participate receive the MUSPAL360 program in addition to standard palliative care, with no control group or randomization. A qualitative component is embedded within the study, collecting participants' and caregivers' subjective experience at the end of each session through a funnel-style question guide; qualitative data are analyzed independently and subsequently integrated with quantitative results.
As a feasibility study, MUSPAL360 does not test confirmatory hypotheses. Instead, pre-specified progression criteria (covering eligibility, consent, session-by-session attrition, data completeness, and adverse events) will inform the decision on whether to proceed to a future confirmatory study. The stepwise decline in expected attrition thresholds across sessions reflects the anticipated clinical deterioration typical of hospitalized palliative care populations, rather than a study design limitation.
Sample size was determined by the precision required to estimate feasibility metrics, not by statistical power to detect clinical effects. A minimum of 40 participants will be recruited, accounting for expected attrition at each stage of the program (approximately 20% prior to Session 1, 30% between Sessions 1 and 2, and 40-50% between Sessions 2 and 3), resulting in an estimated 13-15 evaluable participants at program completion. This sample size allows feasibility proportions to be estimated with 95% confidence intervals of approximately ±15-16 percentage points, adequate precision to guide the viability of future studies. Statistical analysis will be predominantly descriptive: progression criteria will be reported as proportions with 95% confidence intervals (Clopper-Pearson exact method), and exploratory secondary outcomes will be analyzed without correction for multiple comparisons or confirmatory interpretation.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- This is a single-arm feasibility study. All eligible participants who consent receive the three-session MUSPAL360 music therapy program in addition to standard palliative care. There is no control group or randomization; the study was designed as single-arm following ethics committee guidance regarding randomization in this vulnerable, hospitalized population
| Arm | Type | Receives |
|---|---|---|
| MUSPAL360 | Experimental | Behavioral: Music Therapy with Virtual Reality (Session 1), Behavioral: Significant Song Choice (Session 2), Behavioral: Biographical Musical Legacy (Session 3)All eligible patients who consent to participate receive the three-session MUSPAL360 music therapy program (music therapy with virtual reality, significant song choice, and biographical musical legacy) in addition to standard palliative care. There is no control group or randomization |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Adult patients ≥18 years of age with advanced cancer, defined using the NECPAL-CCOMS instrument Hospitalized in the Internal Medicine Service or the Integral Care Unit (UCIA) of HUA and attended by the Palliative Care team Expected hospital stay of at least 7 consecutive days at the time of inclusion (per treating medical team's judgment) Willing to participate and able to sign Informed Consent after receiving a full explanation from the Principal Investigator At least one symptom scoring ≥7 points on the ESAS-r scale Able to maintain alertness and adequate responsiveness during 30-45 minute sessions Able to maintain a bed position of at least 45° for use of the virtual reality headset No cognitive impairment, defined as 0-2 errors on the Short Portable Mental Status Questionnaire (SPMSQ-Pfeiffer), with correction for educational level per the original instrument Functional hearing sufficient to listen to music (with or without hearing aids)
Key exclusion criteria (1 listed)
- Patients in active agonal phase (last 48-72 hours of life, per medical team's judgment) Active, uncontrolled delirium, assessed using the Confusion Assessment Method (CAM) Epilepsy or history of photosensitive seizures Requiring palliative sedation for refractory symptoms Strict contact isolation precluding entry of musical instruments and equipment into the room
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Music Therapy with Virtual Reality (Session 1)First session of the MUSPAL360 program (30/40 minutes), combining live music therapy with immersive 360° virtual reality experiences (Oculus Quest 2) focused on relaxation and support. The music therapist adjusts musical parameters in real time based on the patient's vital signs. Family members may participate through guided imagery with the same live music. | Behavioural | MUSPAL360 |
| Significant Song Choice (Session 2)Second session of the MUSPAL360 program (45 minutes), using a structured guided-question format for the patient to select biographically meaningful songs, live-performed or played, followed by verbal processing of emotional experiences. Family may participate in the collaborative song selection. | Behavioural | MUSPAL360 |
| Biographical Musical Legacy (Session 3)Third session of the MUSPAL360 program (45 minutes), using five chronological biographical questions to guide a musical life review. The session is audio-recorded to create a legacy playlist delivered to the patient and/or family via link or QR code. | Behavioural | MUSPAL360 |
Primary outcome
Eligibility Rate
Time frame: Through study completion, an average of 15 months
Proportion of patients identified by the CP team who meet inclusion criteria (progression threshold: ≥50%)
Consent Rate
Time frame: Through study completion, an average of 15 months
Proportion of eligible patients who consent to participate (≥70%)
Session 1 Arrival Rate
Time frame: Up to 7 days after enrollment
Proportion of participants who initiate Session 1 (≥70%)
Session 1 Completion Rate
Time frame: Up to 7 days after enrollment
Proportion of initiated Session 1s completed without interruption (≥80%)
Session 2 Arrival Rate
Time frame: Up to 7 days after enrollment
Proportion of participants who initiate Session 2 (≥60%)
Session 2 Completion Rate
Time frame: Up to 7 days after enrollment
Proportion of initiated Session 2s completed without interruption (≥80%)
Session 3 Arrival Rate
Time frame: Through study completion
Proportion of participants who initiate Session 3 (≥50%)
Session 3 Completion Rate
Time frame: Through study completion, an average of 15 months
Proportion of initiated Session 3s completed without interruption (≥80%)
Data Completeness
Time frame: Up to 7 days after enrollment
Proportion of required REDCap fields completed, calculated over sessions actually performed (≥80%)
Adverse Event Rate
Time frame: Up to 7 days after enrollment
Proportion of sessions with adverse events attributable to the intervention (dizziness/nausea from VR headset, significant emotional distress, session interruption due to intolerance, or need for immediate clinical intervention) (<5%)
8 secondary outcomes
Change in Global Symptom Burden (ESAS-r)
Time frame: Immediately before and after each of the 3 sessions, and at program completion, up to 7 days after enrollment
Change in Spiritual Wellbeing (FACIT-Sp-12, Argentine validation)
Time frame: Immediately before and after Session 1 only, up to 7 days after enrollment
Change in Perceived Relaxation (VAS)
Time frame: Immediately before and after Session 2 only, up to 7 days after enrollment
Change in Perceived Social Support (VAS)
Time frame: Immediately before and after Session 2 only, up to 7 days after enrollment
Patient Global Rating of the Program
Time frame: Time Frame: At program completion, up to 7 days after enrollment
Caregiver Global Rating of the Program
Time frame: At program completion, up to 7 days after enrollment
Patient Subjective Experience (Qualitative)
Time frame: After each of the 3 sessions and at program completion, up to 7 days after enrollment
Caregiver Subjective Experience (Qualitative)
Time frame: After each of the 3 sessions and at program completion, up to 7 days after enrollment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Sep 2026.
- BackgroundDneaster D, Dileo C. Levels of practice in music therapy at the end of life. In: Dileo C, Loewy J, editors. Music Therapy at the End of Life. Cherry Hill: Jeffrey Books; 2005.
- Background: PubMed 41922094Iturri A, Najun M, Vazquez N, Alonso-Babarro A. Music therapy interventions on symptom management in adults with advanced cancer - multisession longitudinal impact: systematic review. BMJ Support Palliat Care. 2026 Aug 28;16(5):1034-1042. doi: 10.1136/spcare-2025-005913.
- Background: PubMed 42219716Iturri A, Bertella A, Dovidas MN, Spector J, Alonso Babarro A. Music Therapy Combined with Virtual Reality Reduces Prevalent Symptoms in Adult Patients with Advanced Cancer: Randomized Clinical Trial. J Palliat Med. 2026 May;29(5):594-601. doi: 10.1177/10966218251407902. Epub 2026 Jan 9.
- Individual participant dataSharing planned: No
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Agustina Iturri principal investigator
Austral University, Argentina
Questions about this trial
What is this clinical trial studying?
A study testing Music Therapy with Virtual Reality (Session 1), Significant Song Choice (Session 2) and Biographical Musical Legacy (Session 3) in people with Cancer and Palliative Care, run by Austral University, Argentina.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 21 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Agustina Iturri, Phd student (01158540318, agustina.iturri@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Eligibility Rate (time frame: Through study completion, an average of 15 months). The study lists 10 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07831148, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2026.